{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:45:26Z","timestamp":1763016326632},"reference-count":50,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[1999,12,1]],"date-time":"1999-12-01T00:00:00Z","timestamp":944006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":7328,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[1999,12]]},"DOI":"10.1023\/a:1008377724139","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T14:41:38Z","timestamp":1040568098000},"page":"1493-1498","source":"Crossref","is-referenced-by-count":35,"title":["Pentostatin in T-cell malignancies \u2013 a phase II trial of the EORTC"],"prefix":"10.1016","volume":"10","author":[{"given":"A.D.","family":"Ho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Suciu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Stryckmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"De Cataldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Willemze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Thaler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Peetermans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Solbu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Dardenne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Zittoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1023\/A:1008377724139_bb0005","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/jhet.5570110438","article-title":"A novel adenosine and araA deaminase inhibitor, (R)-3-(2-deoxy-P-D-erythro-pentofurano-syl)-3,6,7,8-tetra-hydroamidazo (4,5-d) (1,3) diazepin-8-ol","volume":"11","author":"Woo","year":"1974","journal-title":"J Heterocyclic Chem"},{"key":"10.1023\/A:1008377724139_bb0010","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0140-6736(72)92345-8","article-title":"Adenosine deaminase deficiency in two patients with severely impaired cellular immunity","volume":"2","author":"Giblett","year":"1972","journal-title":"Lancet"},{"key":"10.1023\/A:1008377724139_bb0015","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF00435411","article-title":"The clinical pharmacology of the adenosine deaminase inhibitor 2\u2019-deoxycoformycin","volume":"5","author":"Smyth","year":"1980","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1023\/A:1008377724139_bb0020","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood.V57.3.406.406","article-title":"The biochemical and clinical consequences of 2\u2019-deoxycoformycin in refractory lymphoproliferative malignancy","volume":"57","author":"Grever","year":"1981","journal-title":"Blood"},{"key":"10.1023\/A:1008377724139_bb0025","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1073\/pnas.73.8.2867","article-title":"Trimmer KB et al","volume":"73","author":"Mills","year":"1976","journal-title":"Purine metabolism in adenosine deaminase deficiency. Proc Natl Acad Sci USA"},{"key":"10.1023\/A:1008377724139_bb0030","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1749-6632.1985.tb27103.x","article-title":"Biochemical consequences of adenosine deaminase inhibition in vivo: Differential effects in acute and chronic T-cell leukemia","volume":"45","author":"Mitchell","year":"1985","journal-title":"Ann NY Acad Sci"},{"key":"10.1023\/A:1008377724139_bb0035","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood.V62.2.419.419","article-title":"Deoxyribonucleotide triphosphate accumulation by leukemic cells","volume":"62","author":"Mitchell","year":"1983","journal-title":"Blood"},{"key":"10.1023\/A:1008377724139_bb0040","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1182\/blood.V72.6.1884.1884","article-title":"Clinical response to deoxycoformycin in chronic lymphoid neoplasms and biochemical changes in circulating malignant cells in vivo","volume":"72","author":"Ho","year":"1988","journal-title":"Blood"},{"key":"10.1023\/A:1008377724139_bb0045","first-page":"209","article-title":"Induction of intracellular and plasma 2\u2019.5\u2019-oligoadenylate synthetase by pentostatin","volume":"6","author":"Ho","year":"1992","journal-title":"Leukemia"},{"key":"10.1023\/A:1008377724139_bb0050","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0140-6736(80)90060-4","article-title":"Remission induction with adenosine deaminase inhibitor 2\u2019-deoxycoformycin in thy-lymphoblastic leukaemia","volume":"26","author":"Prentice","year":"1980","journal-title":"Lancet"},{"key":"10.1023\/A:1008377724139_bb0055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood.V58.1.91.91","article-title":"Clinical pharmacology of deoxycoformycin","volume":"58","author":"Major","year":"1981","journal-title":"Blood"},{"key":"10.1023\/A:1008377724139_bb0060","first-page":"3343","article-title":"Phase I study of 2\u2019-deoxycoformycin in acute lymphoblastic leukemia","volume":"41","author":"Poplack","year":"1981","journal-title":"Cancer Res"},{"key":"10.1023\/A:1008377724139_bb0065","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood.V57.3.406.406","article-title":"The biochemical and clinical consequences of 2\u2019-deoxycoformycin in refractory lymhoproliferative malignancy","volume":"57","author":"Grever","year":"1981","journal-title":"Blood"},{"key":"10.1023\/A:1008377724139_bb0070","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1200\/JCO.1985.3.9.1196","article-title":"Low-dose deoxycoformycin in lymphoid malignancy","volume":"3","author":"Grever","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008377724139_bb0075","first-page":"16","article-title":"A new chemotherapeutic agent: Deoxycoformycin (pentostatin)","volume":"31","author":"Dillman","year":"1994","journal-title":"Semin Hematol"},{"key":"10.1023\/A:1008377724139_bb0080","first-page":"S103","article-title":"Clinical experience with 2\u2019-deoxycoformycin Hematol","volume":"38","author":"Catovsky","year":"1996","journal-title":"Cell Ther"},{"key":"10.1023\/A:1008377724139_bb0085","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.4049\/jimmunol.121.5.1726","article-title":"Differential sensitivity of human leukemic T-cell lines and B-cell lines to growth inhibition by deoxyadenosine","volume":"121","author":"Carson","year":"1978","journal-title":"J Immunol"},{"key":"10.1023\/A:1008377724139_bb0090","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S0140-6736(81)91491-4","article-title":"Therapeutic selectivity of and prediction of response of 2\u2019-deoxycoformycin in acute leukaemia","volume":"5","author":"Prentice","year":"1981","journal-title":"Lancet"},{"key":"10.1023\/A:1008377724139_bb0095","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1995.13.4.974","article-title":"Randomized comparison of pentostatin versus interferon-\u03b1-2a in previously untreated patients with hairy cell leukemia: An intergroup study","volume":"13","author":"Grever","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008377724139_bb0100","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jnci\/85.8.658","article-title":"Pentostatin in prolymphocytic leukemia: Phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group","volume":"85","author":"Dohner","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1023\/A:1008377724139_bb0105","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/jnci\/82.17.1416","article-title":"Pentostatin in refractory chronic lymphocytic leukemia: A phase II trial of the European Organization for Research and Treatment of Cancer","volume":"82","author":"Ho","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"10.1023\/A:1008377724139_bb0110","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1200\/JCO.1989.7.10.1533","article-title":"Response to pentostatin in hairy-cell leukemia refractory to interferon-\u03b1","volume":"10","author":"Ho","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008377724139_bb0115","series-title":"Malignant Lymphomas Other Than Hodgkin\u2019s Disease: Histology, Ultrastructure, Immunology","author":"Lennert","year":"1978"},{"key":"10.1023\/A:1008377724139_bb0120","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/1097-0142(19830415)51:8<1434::AID-CNCR2820510818>3.0.CO;2-4","article-title":"Subtypes of T-cell chronic lymphatic leukemia","volume":"51","author":"Huhn","year":"1983","journal-title":"Cancer"},{"key":"10.1023\/A:1008377724139_bb0125","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1182\/blood.V86.3.1163.1163","article-title":"True T-cell chronic lymphocytic leukemia: A morphologic and immunophenotypic study of 25 cases","volume":"86","author":"Hoyer","year":"1995","journal-title":"Blood"},{"key":"10.1023\/A:1008377724139_bb0130","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1200\/JCO.1991.9.7.1298","article-title":"Mycosis fungoides and the Sezary syndrome: A review of pathogenesis, diagnosis and therapy","volume":"9","author":"Kuzel","year":"1980","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008377724139_bb0135","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-121-8-199410150-00007","article-title":"Systemic therapy of cutaneous T-cell lymphomas (myosis fungoides and the Sezary syndrome)","volume":"121","author":"Bunn","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1023\/A:1008377724139_bb0140","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-2141.1994.tb08308.x","article-title":"Peripheral T-cell non-Hodgkin\u2019s lymphomas of low malignancy: Prospective study of 25 patients with pleomorphic small-cell lymphoma, lymphoepitheloid cell (Lennert\u2019s) lymphoma and T-zone lymphoma","volume":"87","author":"Siegert","year":"1994","journal-title":"The Kiel Lymphoma Study Group. Br J Hematol"},{"key":"10.1023\/A:1008377724139_bb0145","series-title":"Statistics with Confidence \u2014Confidence Intervals and Statistical Guidelines","author":"Gardner","year":"1989"},{"key":"10.1023\/A:1008377724139_bb0150","series-title":"The calculation and interpretation of survival curves","author":"Peto","year":"1988"},{"key":"10.1023\/A:1008377724139_bb0155","series-title":"Cancer Clinical Trials: Methods and Practice","author":"Buyse","year":"1992"},{"key":"10.1023\/A:1008377724139_bb0160","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/archderm.1995.01690210109021","article-title":"New concepts in the classification of cutaneous lymphomas","volume":"131","author":"Willemze","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1023\/A:1008377724139_bb0165","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0950-3536(96)80052-7","article-title":"Management of cutaneous lymphoma","volume":"9","author":"Russel-Jones","year":"1996","journal-title":"Baillieres-Clin Haematol"},{"key":"10.1023\/A:1008377724139_bb0170","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3109\/10428199609052422","article-title":"Classification of peripheral T-cell lymphomas: Cytogenetic findings support the Updated Kiel Classification","volume":"20","author":"Schlegelberger","year":"1996","journal-title":"Leuk Lymph"},{"key":"10.1023\/A:1008377724139_bb0175","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1182\/blood.V61.2.279.279","article-title":"An investigation of 2\u2019-deoxycoformycin in the treatment of cutaneous T-cell lymphoma","volume":"61","author":"Grever","year":"1983","journal-title":"Blood"},{"key":"10.1023\/A:1008377724139_bb0180","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.1991.9.4.565","article-title":"Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease","volume":"9","author":"Cummings","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008377724139_bb0185","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1200\/JCO.1994.12.12.2588","article-title":"The role of pentostatin in the treatment of T-cell malignancies: Analysis of response rate in 145 patients according to disease subtype","volume":"12","author":"Mercieca","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008377724139_bb0190","unstructured":"Greiner D, Olsen EA, Petroni G. Pentostatin (2\u2019-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma."},{"key":"10.1023\/A:1008377724139_bb0195","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/mpo.2950180307","article-title":"2\u2019-desoxycoformycin (pentostatin) for refractory non-Hodgkin\u2019s lymphoma: A CALGB phase II study","volume":"18","author":"Duggan","year":"1990","journal-title":"Med Pediatr Oncol"},{"key":"10.1023\/A:1008377724139_bb0200","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000227554","article-title":"Pentostatin (2\u2019-deoxycormycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: Phase II study of the EORTC Early Clinical Trials Group","volume":"53","author":"Monfardini","year":"1996","journal-title":"Oncology"},{"key":"10.1023\/A:1008377724139_bb0205","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood.V87.3.906.bloodjournal873906","article-title":"Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma","volume":"87","author":"Kuzel","year":"1996","journal-title":"Blood"},{"issue":"Suppl","key":"10.1023\/A:1008377724139_bb0210","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/10428199309149111","article-title":"2-Chlorodeoxyadenosine: A new nucleoside agent effective in the treatment of lymphoid malignancies","volume":"10","author":"Saven","year":"1993","journal-title":"Leuk Lymph"},{"key":"10.1023\/A:1008377724139_bb0215","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/jnci\/82.16.1353","article-title":"Activity of fludarabine monophosphate in patients with advanced mycosis fungoides A Southwest Oncology Group study","volume":"82","author":"Von Hof","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"10.1023\/A:1008377724139_bb0220","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1200\/JCO.1994.12.10.2051","article-title":"Phase II trial of fludarabine phosphate and interferon-\u03b1-2a in advanced mycosis fungoides\/ Sezary syndrome","volume":"12","author":"Foss","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008377724139_bb0225","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1200\/JCO.1992.10.12.1907","article-title":"Phase II study of pentostatin and intermittent high-dose recombinant interferon-\u03b1-2a in advanced mycosis fungoides\/S\u00e9zary syndrome","volume":"10","author":"Foss","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008377724139_bb0230","doi-asserted-by":"crossref","first-page":"484","DOI":"10.7326\/0003-4819-101-4-484","article-title":"Recombinant leukocyte \u03b1-interferon: An active agent in advanced cutaneous T-cell lymphomas","volume":"101","author":"Bunn PA","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1023\/A:1008377724139_bb0235","first-page":"394","article-title":"Continuous infusion of T101 monoclonal antibody in chronic lymphocytic leukemia and cutaneous T-cell lymphoma","volume":"5","author":"Dillman","year":"1986","journal-title":"J Bio Response Modifiers"},{"key":"10.1023\/A:1008377724139_bb0240","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.1987.5.4.562","article-title":"Radioummunodetection and radioimmunotherapy of cutaneous T-cell lymphomas using an 131l-labeled monoclonal antibody: An Illinois Cancer Council Study","volume":"5","author":"Rosen","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008377724139_bb0245","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.V84.6.1765.1765","article-title":"Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: Correlation of activity and interleukin-2 receptor expression in a phase II study","volume":"84","author":"Foss","year":"1994","journal-title":"Blood"},{"key":"10.1023\/A:1008377724139_bb0250","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1182\/blood.V79.10.2547.bloodjournal79102547","article-title":"Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) hematologic malignancies expressing the IL-2 receptor","volume":"79","author":"LeMaistre","year":"1992","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419574749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419574749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/10\/12\/1493\/19477429\/10-12-1493.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T16:45:30Z","timestamp":1682009130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419574749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,12]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[1999,12]]}},"alternative-id":["S0923753419574749"],"URL":"https:\/\/doi.org\/10.1023\/a:1008377724139","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[1999,12]]}}}